SUDO-550, an oral therapy for MS, was found to be safe and to reach the brain in its first human clinical trial, trial ...

MS patients have increased risks of developing other autoimmune diseases, necessitating careful treatment planning to balance efficacy and risk. Dimethyl fumarate, anti-CD20 antibodies, and ozanimod ...

Two key symptoms that can arise soon after a diagnosis of multiple sclerosis (MS) could predict how swiftly the illness will progress and suggest best treatment options, new research shows. Photo by ...

Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. Speaking to Fierce Pharma, CEO Daniel Vitt shares insights ...

About 1 million people in the U.S. live with multiple sclerosis, a chronic autoimmune disease that inflames the nervous ...

Cabaletta Bio, Inc. (($CABA)) announced an update on their ongoing clinical study. RESET-MS is a Phase 1/2 open-label study conducted by Cabaletta ...

Considering the CLARITY Phase III study results, cladribine tablets may offer several improvements over existing MS drugs including a simple, short-course annual dosing regimen of either 2 or 4 weeks ...

Panelists discuss how disability progression can be measured through practical clinical tools like patient-reported outcomes, timed walking tests, and dexterity assessments rather than relying solely ...

For people living with multiple sclerosis (MS), the search for effective treatment options can feel like a never-ending journey. While disease-modifying therapies (DMTs) have improved outcomes for ...

Modern disease-modifying drugs (DMTs) have revolutionized the treatment of relapsing-remitting multiple sclerosis (MS). However, their use during pregnancy has long been concerning. A study published ...